DongKoo Bio & Pharma Co., Ltd. Logo

DongKoo Bio & Pharma Co., Ltd.

Pharma leader in dermatology, developing treatments, probiotics, and investing in biotech therapies.

006620 | KO

Overview

Corporate Details

ISIN(s):
KR7006620009
LEI:
Country:
South Korea
Address:
서울특별시 송파구 법원로 114, B동 14층, 송파구
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

DongKoo Bio & Pharma Co., Ltd. is a pharmaceutical company founded in 1970 that engages in the research, development, manufacturing, and sale of medical products. The company is a recognized leader in the dermatology prescription market and also offers a portfolio of products including antihistamines, probiotics, and treatments for gum disease. Strategically expanding beyond traditional pharmaceuticals, the company pursues an 'Open Innovation' model to develop differentiated pipelines and invest in future technologies, with a focus on biotechnology and stem cell-based therapies. It operates with world-class research centers and GMP (Good Manufacturing Practice) certified facilities.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-08-14 00:00
Interim Report
반기보고서 (2025.06)
Korean 2.1 MB
2025-07-02 00:00
M&A Activity
합병등종료보고서(합병)
Korean 16.5 KB
2025-06-18 00:00
Major Shareholding Notification
주식등의대량보유상황보고서(일반)
Korean 125.5 KB
2025-05-15 00:00
Quarterly Report
분기보고서 (2025.03)
Korean 2.0 MB
2025-04-30 00:00
M&A Activity
주요사항보고서(회사합병결정)
Korean 72.2 KB
2025-04-30 00:00
Pre-Annual General Meeting Information
주주명부폐쇄기간또는기준일설정
Korean 5.2 KB
2025-04-23 00:00
Major Shareholding Notification
주식등의대량보유상황보고서(일반)
Korean 125.8 KB
2025-04-02 00:00
Major Shareholding Notification
주식등의대량보유상황보고서(일반)
Korean 125.8 KB
2025-03-31 00:00
Share Issue/Capital Change
증권발행결과(자율공시)
Korean 6.2 KB
2025-03-31 00:00
Transaction in Own Shares
자기주식처분결과보고서
Korean 32.1 KB
2025-03-27 00:00
Capital/Financing Update
주요사항보고서(교환사채권발행결정)
Korean 42.7 KB
2025-03-27 00:00
Transaction in Own Shares
주요사항보고서(자기주식처분결정)
Korean 37.7 KB
2025-03-26 00:00
Post-Annual General Meeting Information
정기주주총회결과
Korean 28.5 KB
2025-03-26 00:00
Remuneration Information
주식매수선택권부여에관한신고
Korean 17.3 KB
2025-03-26 00:00
Board/Management Information
사외이사의선임ㆍ해임또는중도퇴임에관한신고
Korean 13.3 KB

Automate Your Workflow. Get a real-time feed of all DongKoo Bio & Pharma Co., Ltd. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for DongKoo Bio & Pharma Co., Ltd.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for DongKoo Bio & Pharma Co., Ltd. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Active Biotech Logo
Develops immunology-based drugs for cancer and inflammatory diseases with high unmet medical need.
Sweden
ACTI
ACTUATE THERAPEUTICS, INC. Logo
Clinical-stage biopharma developing a novel GSK-3 inhibitor for hard-to-treat cancers.
United States of America
ACTU
AcuCort AB Logo
Develops a rapid oral film for acute allergies, croup, and chemo-induced nausea.
Sweden
ACUC
Acurx Pharmaceuticals, Inc. Logo
Developing a new class of antibiotics to treat priority Gram-positive bacterial infections.
United States of America
ACXP
Adagene Inc. Logo
Develops novel antibody-based immunotherapies for cancer using an AI-driven discovery platform.
United States of America
ADAG
Adaptimmune Therapeutics PLC Logo
Develops novel T-cell therapies to treat solid tumors by engineering a patient's own immune cells.
United States of America
ADAP
ADBIOTECH Co.,Ltd. Logo
Develops egg-based IgY antibodies as vaccine/antibiotic alternatives for animal and human health.
South Korea
179530
ADC Therapeutics SA Logo
Develops targeted antibody-drug conjugates for hematological and solid tumors.
United States of America
ADCT
ADIAL PHARMACEUTICALS, INC. Logo
Develops personalized, genetically-targeted drugs for treating Alcohol Use Disorder and addiction.
United States of America
ADIL
Adicet Bio, Inc. Logo
Developing off-the-shelf gamma delta T cell therapies for cancer and autoimmune diseases.
United States of America
ACET

Talk to a Data Expert

Have a question? We'll get back to you promptly.